MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
9.74
-0.54 (-5.25%)
At close: Mar 13, 2026, 4:00 PM EDT
9.66
-0.08 (-0.82%)
After-hours: Mar 13, 2026, 7:56 PM EDT
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
45.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Atara Biotherapeutics | 151.93M |
| Immutep | 5.28M |
| Plus Therapeutics | 5.26M |
| Nutriband | 2.28M |
| Aligos Therapeutics | 2.19M |
| Lisata Therapeutics | 1.07M |
| Rallybio | 674.00K |
INKT News
- 3 days ago - Why Is MiNK Therapeutics Stock Trading Lower On Wednesday? - Benzinga
- 4 days ago - MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally - Benzinga
- 4 days ago - MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers - GlobeNewsWire
- 5 weeks ago - MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia - GlobeNewsWire
- 2 months ago - MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease - GlobeNewsWire
- 4 months ago - MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors - GlobeNewsWire
- 4 months ago - MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025 - GlobeNewsWire